SCHEMBL30299133

SCHEMBL30299133

CCC(CCNS(=O)(=O)c1ccccc1[N+](=O)[O-])NC(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
ALDH1A1 P00352 4/20 0.45
THRB P10828 1/20 0.44
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
MMP1 P03956 1/20 0.43
MMP2 P08253 1/20 0.43
MMP9 P14780 1/20 0.43
MMP8 P22894 1/20 0.43
MMP13 P45452 1/20 0.43
CYP19A1 P11511 1/20 0.43
NPY5R Q15761 4/20 0.43
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
TRPV4 Q9HBA0 1/20 0.42
LMNA P02545 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25354891 0.89 KMT2A (0.48) KMT2AMEN1ALDH1A1THRBCA1
SCHEMBL25351507 0.86 KMT2A (0.53) KMT2AMEN1ALDH1A1THRBCA1
SCHEMBL5147914 0.86 ALDH1A1 (0.55) KMT2AMEN1ALDH1A1THRBCA1
SCHEMBL1645223 0.85 GSTP1 (0.47) KMT2AMEN1ALDH1A1THRBCA1
SCHEMBL1645219 0.85 GSTP1 (0.47) KMT2AMEN1ALDH1A1THRBCA1
SCHEMBL30191345 0.84 ALDH1A1 (0.44) KMT2AMEN1ALDH1A1THRBCA1
SCHEMBL14458703 0.82 KMT2A (0.52) KMT2AMEN1ALDH1A1THRBCA1
SCHEMBL1646038 0.80 KMT2A (0.48) KMT2AMEN1ALDH1A1THRBCA1
SCHEMBL1646035 0.80 KMT2A (0.48) KMT2AMEN1ALDH1A1THRBCA1
SCHEMBL25350892 0.80 KMT2A (0.50) KMT2AMEN1ALDH1A1THRBCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109732-A1 LIPID AMINES MODERNATX INC (US) 2026-04-23 US disclosed
US-20250235531-A1 MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS MODERNATX, INC. (US) 2025-07-24 US disclosed
EP-4475882-A1 MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS ModernaTX, Inc. (US) 2024-12-18 EP disclosed
EP-4423107-A1 LIPID AMINES ModernaTX, Inc. (US) 2024-09-04 EP disclosed
WO-2023076598-A1 LIPID AMINES MODERNATX, INC. (US) 2023-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250235531-A1 MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS MUC1, RNMT, FABP2 KMT2A 2443/4885MEN1 1496/4885ALDH1A1 3775/4885
US-20260109732-A1 LIPID AMINES LDLR, NPC1, PHOSPHO1 KMT2A 1139/4885MEN1 1812/4885ALDH1A1 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.